| Drug Name |
Peginterferon beta-1a |
| Drug ID |
BADD_D01697 |
| Description |
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings.[L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.[L31428] Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. |
| Indications and Usage |
For the treatment of patients with relapsing forms of multiple sclerosis. |
| Marketing Status |
Prescription |
| ATC Code |
L03AB13 |
| DrugBank ID |
DB09122
|
| KEGG ID |
D10483
|
| MeSH ID |
C428112
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0LW4O
|
| NDC Product Code |
64406-012; 64406-016; 64406-015; 64406-011; 64406-017 |
| Synonyms |
peginterferon beta-1a | polyethylene glycol-interferon-beta-1a | PEG IFN-beta-1a | polyethylene glycol-interferon beta-1a | Plegridy |
